Radionuclide scanning to diagnose Parkinson disease: Is it cost-effective?

Nature Clinical Practice Neurology

Volumn 5, Issue 1, 2009, Pages 10-11

  Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL) N (3 FLUOROPROPYL)NORTROPANE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ESSENTIAL TREMOR; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; NOTE; PARKINSON DISEASE; PRIORITY JOURNAL; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT INDICATION;

EID: 58249086346     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0986     Document Type: Note

References (5)

1. 123I-FP-CIT study group. Mov Disord 15: 503-510
2. 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. Mov Disord [doi:10.1002/mds.22278]
3. Dodel RC et al. (2003) Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: A decision-analytic approach. Mov Disord 18 (suppl 7): S52-S62
4. Jankovic J et al. (2000) The evolution of diagnosis in early Parkinson disease: Parkinson Study Group. Arch Neurol 57: 369-372
5. Olanow CW and Rascol O (2008) Early rasagiline treatment slows UPDRS decline in the ADAGIO delayed start study. Ann Neurol 64 (suppl 12): S3